Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Erin A Bohula , Harriette Van Spall Added: 3 weeks ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more
Author(s): Matthias Bossard Added: 1 month ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus… View more
Author(s): P Kasi Ramanathan Added: 1 month ago
TCT 2025 - Sub-anlysis findings showed positive safety and efficacy outcomes of the PASCAL Precision system in degenerative mitral regurgitation (DMR) patients.Dr P Kasi Ramanathan (Promedica Toledo Hospital, US) joins us on-site at TCT 2025 to share the findings from a sub-analysis looking at the affect of implant location and leaflet lesion location on the safety and effectiveness of the PASCAL… View more
Author(s): Ole De Backer Added: 4 months ago
Explore the challenges and outcomes of TAVI in bicuspid aortic stenosis with Prof Ole De Backer (Rigshospitalet, Copenhagen, Denmark).This presentation, part of a comprehensive two-part series on complex cases in interventional cardiology, examines the unique anatomical considerations and clinical evidence when treating bicuspid valve disease with transcatheter techniques.Prof De Backer addresses… View more
Author(s): Nicole Karam Added: 4 months ago
Discover the sex-specific challenges in aortic stenosis diagnosis and management with Prof Nicole Karam (European Hospital Georges Pompidou, Paris, FR).This presentation, part of a comprehensive two-part series on complex cases in interventional cardiology, explores the critical pathophysiological differences between men and women that impact diagnostic approaches and therapeutic decision-making… View more
Author(s): Gregory Piazza Added: 3 months ago
ESC Congress 2025 - HI-PRO shows apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism when compared to placebo at 12 months.Dr Gregory Piazza (Brigham and Women's Hospital, US) joins us to discuss findings from the HI-PRO trial, evaluating extended-duration low-intensity apixaban versus placebo for secondary prevention in high-risk patients with provoked… View more
Author(s): Neha Pagidipati Added: 3 months ago
ESC Congress 2025 - KARDIA 3 finds that a single dose of zilebesiran 300mg reduced office systolic blood pressure at month three compared to placebo, informing the dose, design and patient population for the upcoming zilebesiran phase III Cardiovascular outcomes trial.Dr Neha Pagidipati (Duke University Medical Center, US) joins us to discuss findings from the KARDIA-3 trial, evaluating… View more
Author(s): Joo-Yong Hahn Added: 8 months ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more
Author(s): Steven E Nissen Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial… View more